Literature DB >> 8714313

Catecholamines in attention-deficit hyperactivity disorder: current perspectives.

S R Pliszka1, J T McCracken, J W Maas.   

Abstract

OBJECTIVE: To provide an update on the "catecholamine hypothesis" of attention-deficit hyperactivity disorder (ADHD).
METHOD: Recent work examining the measurement of the norepinephrine, epinephrine, and dopamine systems in ADHD and normal subjects is reviewed and discussed in the context of recent neuroimaging and animal studies.
RESULTS: While data clearly indicate a role for all three of the above neurotransmitters in ADHD, a hypothesis suggesting "too much" or "too little" of a single neurotransmitter will no longer suffice. The central norepinephrine system may be dysregulated in ADHD, such that this system does not efficiently "prime" the cortical posterior attention system to external stimuli. Effective mental processing of information involves an anterior "executive" attention system which may depend on dopaminergic input. The peripheral epinephrine system may be a critical factor in the response of individuals with ADHD to stimulant medication.
CONCLUSION: A multistage hypothesis is presented which emphasizes the interaction of norepinephrine, epinephrine, and dopamine in modulation of attention and impulse control.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8714313     DOI: 10.1097/00004583-199603000-00006

Source DB:  PubMed          Journal:  J Am Acad Child Adolesc Psychiatry        ISSN: 0890-8567            Impact factor:   8.829


  48 in total

1.  α₂- and β-adrenoceptors involvement in nortriptyline modulation of auditory sustained attention and impulsivity.

Authors:  Swagata Roychowdhury; Zulma Peña-Contreras; Jason Tam; Amulya Yadlapalli; Lu Dinh; Justin Andrew Nichols; Debarshi Basu; Marco Atzori
Journal:  Psychopharmacology (Berl)       Date:  2012-01-21       Impact factor: 4.530

2.  ADHD Rating Scale IV: psychometric properties from a multinational study as a clinician-administered instrument.

Authors:  S Zhang; D E Faries; M Vowles; D Michelson
Journal:  Int J Methods Psychiatr Res       Date:  2005       Impact factor: 4.035

3.  New developments in the treatment of attention-deficit/hyperactivity disorder in primary care.

Authors: 
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2006

4.  Attention-deficit hyperactivity disorder and the adrenergic receptors alpha 1C and alpha 2C.

Authors:  C L Barr; K Wigg; G Zai; W Roberts; M Malone; R Schachar; R Tannock; J L Kennedy
Journal:  Mol Psychiatry       Date:  2001-05       Impact factor: 15.992

5.  Locus coeruleus neuronal activity correlates with behavioral response to acute and chronic doses of methylphenidate (Ritalin) in adolescent rats.

Authors:  Natasha Kharas; Cruz Reyes-Vazquez; Nachum Dafny
Journal:  J Neural Transm (Vienna)       Date:  2017-07-20       Impact factor: 3.575

Review 6.  Animal models to guide clinical drug development in ADHD: lost in translation?

Authors:  Jeffery R Wickens; Brian I Hyland; Gail Tripp
Journal:  Br J Pharmacol       Date:  2011-10       Impact factor: 8.739

7.  Acute and sub-chronic functional neurotoxicity of methylphenidate on neural networks in vitro.

Authors:  K V Gopal; B R Miller; G W Gross
Journal:  J Neural Transm (Vienna)       Date:  2007-06-18       Impact factor: 3.575

Review 8.  Pharmacological models of ADHD.

Authors:  R M Kostrzewa; J P Kostrzewa; R A Kostrzewa; P Nowak; R Brus
Journal:  J Neural Transm (Vienna)       Date:  2007-11-12       Impact factor: 3.575

Review 9.  Non-stimulant medications in the treatment of ADHD.

Authors:  Tobias Banaschewski; Veit Roessner; Ralf W Dittmann; Paramala Janardhanan Santosh; Aribert Rothenberger
Journal:  Eur Child Adolesc Psychiatry       Date:  2004       Impact factor: 4.785

10.  Dopamine transporter genotype and stimulant side effect factors in youth diagnosed with attention-deficit/hyperactivity disorder.

Authors:  Reut Gruber; Ridha Joober; Natalie Grizenko; Bennett L Leventhal; Edwin H Cook; Mark A Stein
Journal:  J Child Adolesc Psychopharmacol       Date:  2009-06       Impact factor: 2.576

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.